undamentalytics Newsletter
Sign in

DaVita revenue

DaVita's revenue was $13.64bn in fiscal 2025, up 6.5% on the year before. Since fiscal 2016 ($10.71bn) it has grown at a compound 2.7% a year. Over the last twelve months it was $14.17bn.

Revenue history

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue10.710.911.411.411.611.611.612.112.813.614.2
Growth on the year before—+1.6%+4.9%−0.1%+1.4%+0.6%−0.1%+4.6%+5.6%+6.5%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
US Dialysis and Related Lab Services $11.7B 86.0% ▲ 3.6%
All Other Segments $1.9B 14.0% ▲ 27.7%

From DaVita's 10-K filed February 11, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Services: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
DaVita $14.17bn 6.4% 6.0%
Labcorp $14.59bn 6.0% 6.6%
Brightspring Health Services, Inc. $15.25bn 35.9% —
Quest Diagnostics $11.84bn 9.1% 8.4%
Agilon Health, Inc. $5.92bn 0.3% 22.9%
Option Care Health, Inc. $5.69bn 5.9% 11.3%

Compare with peers

Head to head: DVA vs LHBTSG vs DVADGX vs DVA

More: Health Care Services stocks compared, Health Care sector, rankings of US companies

Figures from DaVita's SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to DaVita.